The Epilepsy Foundation has learned that Pfizer is contacting health care professionals, including pharmacists, about a shortage of DILANTIN 100 mg. According to Pfizer, this product shortage is due to a manufacturing issue and not the result of any performance or safety concerns.
The company expects a limited supply of DILANTIN 100 mg to be available through August 31, 2011 Check your prescription bottle to see if you might be affected by this shortage of Dilantin 100 mg. The Epilepsy Foundation's medical experts recommend that you contact your physician immediately if you use this product. Abrupt withdrawal of phenytoin in patients with epilepsy could lead to serious health issues. Please keep in mind that any change to your therapy should be done only at the direction of physician.
The following Dilantin formulations are still available through normal channels:
•DILANTIN INFATABS® (Phenytoin Tablets, USP) 50 mg ″
•DILANTIN-125® (Phenytoin Oral Suspension, USP) 125 mg ″
•DILANTIN® (Extended Phenytoin Sodium Capsules, USP) 30 mg
If you have any questions, please contact Pfizer Medical Information at 1-800-438-1985.
The Epilepsy Foundation will maintain close communication with Pfizer in order to keep you informed and obtain the most accurate timeline on when this shortage will be resolved.